lunes, 23 de marzo de 2015

actualización en Artritis.

He hecho un curso de medscape sobre Artritis y os aporto esta bibliografia por si os fuera de interes.


  1. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64:640-647. Abstract
  2. Gilek-Seibert K, Prescott K, Kazi S. Outcome assessments in rheumatoid arthritis. Curr Rheumatol Rep. 2013;15:370.
  3. Centers for Medicare and Medicaid Services. 2014 Physician Quality Reporting System (PQRS) Measures List. Accessed November 12, 2014.
  4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509. Abstract
  5. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383:321-332. Abstract
  6. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther. 2014;36:427-435. Abstract
  7. Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010-1014. Abstract
  8. Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis.Rheumatology (Oxford). 2014;53:1742-1751. Abstract
  9. Gensler LS. Glucocorticoids: complications to anticipate and prevent. Neurohospitalist. 2013;3:92-97. Abstract
  10. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171:1045-1051. Abstract
  11. Rau R. Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother. 2014;15:1575-1583. Abstract
  12. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
  13. Zochling J, March L. First do no harm--a bone of contention in rheumatoid arthritis. J Rheumatol. 2002;29:1818-1820. Abstract
  14. Guignat L, de Bucy C, Bertherat J. [Glucocorticoid treatments and adrenal function]. Rev Prat. 2008;58:966-970. Abstract
  15. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. 2007;66:iii56-iii60. Abstract
  16. Cardiel MH. Treat to target strategy in rheumatoid arthritis: real benefits. Reumatol Clin. 2013;9:101-105. Abstract
  17. Bernstein EJ, Kay J, Gibofsky A. Treating rheumatoid arthritis to target: an international initiative. Curr Rev Musculoskelet Med. 2011;4:79-83. Abstract
  18. Smolen JS, Aletaha D, Bijlsma JW, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637. Abstract
  19. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353:1568-1573. Abstract
  20. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269. Abstract
  21. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390. Abstract
  22. Verstappen SM, Jacobs JW, van der Veen MJ, et al; Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449. Abstract
  23. Keystone EC. Are physician-derived joint counts obsolete? J Rheumatol. 2010;37:883-884.
  24. Pincus T, Castrejón I. Are patient self-report questionnaires as "scientific" as biomarkers in "treat-to-target" and prognosis in rheumatoid arthritis? Curr Pharm Des. 2014. [Epub ahead of print]
  25. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-639. Abstract
  26. Dougados MR, van der Heijde DM, Brault Y, Koenig AS, Logeart IS. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). J Rheumatol. 2014;41:1922-1934. Abstract
  27. Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. [Epub ahead of print]
  28. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-681. Abstract
  29. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381:918-929. Abstract
  30. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69:1629-1635. Abstract
  31. Escalante A, Haas RW, del Rincón I. Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests. Arthritis Res Ther. 2004;6:R315-R325. Abstract
  32. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102.
  33. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum (Munch). 2014;66:2675-2684.
  34. Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:183-191. Abstract
  35. Felson DT, Smolen JS, Wells G, et al; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-586. Abstract
  36. Smolen JS, Kay J, Doyle MK, et al; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210-221. Abstract

No hay comentarios:

Publicar un comentario

Danos tu opinion, enriquece el post.